Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Switching to Aflibercept 8mg in Patients With Neovascular AMD Showing Limited Response to Faricimab or Aflibercept 2mg

NCT06683950 is registered in ClinicalTrials.gov with Kim's Eye Hospital as lead sponsor.

NCT NCT06683950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06683950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Switching to Aflibercept 8mg in Patients With Neovascular AMD Showing Limited Response to Faricimab or Aflibercept 2mg
Lead sponsor
Kim's Eye Hospital
Phase
Phase 4
Overall status
Completed
Start date
October 21, 2024
Completion date
July 14, 2026
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration (armd)